These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2515655)

  • 1. Thermal inactivation by sequential dry-heat treatments at sterilizing temperatures (100 degrees C-boiling) of factor VIII and factor IX concentrates to produce sterile concentrates.
    Rubinstein AI; Rubinstein DB
    Vox Sang; 1989; 57(4):272. PubMed ID: 2515655
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined solvent-detergent and 100 degrees C (boiling) sterilizing dry-heat treatment of factor VIII concentrates to assure sterility.
    Rubinstein AI; Rubinstein DB; Coughlin J
    Vox Sang; 1991; 60(1):60. PubMed ID: 1905083
    [No Abstract]   [Full Text] [Related]  

  • 3. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
    Teh LC; Woodfield DG
    Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
    [No Abstract]   [Full Text] [Related]  

  • 4. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
    Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
    Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates.
    Guillaume TA
    Vox Sang; 1993; 65(2):158. PubMed ID: 8212671
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates.
    Heldebrant CM; Gomperts ED; Kasper CK; McDougal JS; Friedman AE; Hwang DS; Muchmore E; Jordan S; Miller R; Sergis-Davenport E
    Transfusion; 1985; 25(6):510-5. PubMed ID: 3934800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization of various heat-treated prothrombin complex concentrates (PCC).
    Yoshioka A; Nakagawa O; Uehara Y; Sakai T; Sugimoto M; Takamiya O; Tanaka I; Fukui H
    Thromb Res; 1987 Aug; 47(4):449-58. PubMed ID: 2958958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of virucidal heat treatment on proteins in human factor VIII concentrates.
    Thomas KB; McGrath KM; Taylor M; Young IF; Herrington RW; Schiff P
    Transfusion; 1988; 28(1):8-13. PubMed ID: 3124306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation factor activity in platelet concentrates.
    Simon TL; Henderson R
    Transfusion; 1979; 19(2):186-9. PubMed ID: 432931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates.
    Hart HF; Hart WG; Crossley J; Perrie AM; Wood DJ; John A; McOmish F
    Vox Sang; 1994; 67(4):345-50. PubMed ID: 7701804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro characterization of various factor VIII concentrates.
    Yoshioka A; Shima M; Nishino M; Yoshikawa N; Fukui H
    Arzneimittelforschung; 1987 Jul; 37(7):753-6. PubMed ID: 3118888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis A transmission by factor IX concentrates.
    Lawlor E; Graham S; Davidson E; Yap PL; Cunningham C; Daly H; Temperley IJ
    Vox Sang; 1996; 71(2):126-8. PubMed ID: 8873425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biological activities of the coagulation factor VIII, IX in platelet concentrates collected by platelet apheresis during preservation].
    Yang JC; Li FQ; Li MH; Ren JK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):162-4. PubMed ID: 16584615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography.
    Orthner CL
    J Lab Clin Med; 1984 Nov; 104(5):816-28. PubMed ID: 6436416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus associated DNA polymerase inactivation in factor IX concentrates.
    Mitra G; Ng PK
    Thromb Res; 1986 Feb; 41(3):291-300. PubMed ID: 3705011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality control in the development of coagulation factor concentrates.
    Snape TJ
    Dev Biol Stand; 1987; 67():141-7. PubMed ID: 3609474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.